Cargando…

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases

BACKGROUND/AIM: Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, it has been proposed that ruxolitinib-induced JAK/STAT pathway inhibition i...

Descripción completa

Detalles Bibliográficos
Autores principales:	TÜRK, Can, OKAY, Müfide, TÜRK, Seyhan, TEMİRCİ, Elif Sena, JAVAD, Osama, AKSU, Salih, SAYINALP, Nilgün, HAZNEDAROĞLU, İbrahim Celalettin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Scientific and Technological Research Council of Turkey 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018380/ https://www.ncbi.nlm.nih.gov/pubmed/30997981 http://dx.doi.org/10.3906/sag-1807-152

Ejemplares similares

The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia
por: Ghasemi, Mehdi, et al.
Publicado: (2019)

In vitro analysis of the renin–angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus
por: Turk, Can, et al.
Publicado: (2020)

Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide
por: Turk, Seyhan, et al.
Publicado: (2020)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
por: Eliaçık, Eylem, et al.
Publicado: (2015)

The Factors Affecting Early Death in Newly Diagnosed APL Patients
por: Ciftciler, Rafiye, et al.
Publicado: (2019)

Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation
por: Çiftçiler, Rafiye, et al.
Publicado: (2021)

Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemia
por: Serefhanoglu, Songul, et al.
Publicado: (2010)

Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines
por: Turk, Seyhan, et al.
Publicado: (2017)

CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation
por: ALADAĞ, Elifcan, et al.
Publicado: (2020)

MON-381 Endocrinological Evaluation of Adult Thalassemia Patients
por: Oguz, Seda Hanife, et al.
Publicado: (2020)

Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study
por: Çiftçiler, Rafiye, et al.
Publicado: (2019)

NK-cell dysfunction of acute myeloid leukemia in relation to the renin–angiotensin system and neurotransmitter genes
por: Turk, Seyhan, et al.
Publicado: (2022)

Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency
por: ALADAĞ, Elifcan, et al.
Publicado: (2019)

JAK-STAT in lymphoproliferative disorders
por: Rabadan, Raul, et al.
Publicado: (2015)

Aggressive Clinicopathological Course of Myeloma with t(3;16) (q21;q22) Cytogenetic Abnormality
por: Bozkurt, Süreyya, et al.
Publicado: (2019)

Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis
por: Çınar, Olgu Erkin, et al.
Publicado: (2020)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
por: Işık, Ayşe, et al.
Publicado: (2013)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine
por: Okay, Mufide, et al.
Publicado: (2019)

Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia
por: Okay, Müfide, et al.
Publicado: (2019)

Indications and Outcomes of Splenectomy for Hematological Disorders
por: Ciftciler, Rafiye, et al.
Publicado: (2019)

Enterotoxins A and B produced by Staphylococcus aureus increase cell proliferation, invasion and cytarabine resistance in acute myeloid leukemia cell lines
por: Turk, Seyhan, et al.
Publicado: (2023)

Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma
por: Ghasemi, Mehdi, et al.
Publicado: (2016)

Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems
por: Bektaş, Özlen, et al.
Publicado: (2016)

Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission
por: Aydın, Mürüvvet Seda, et al.
Publicado: (2017)

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation
por: KARATAŞ, Ayşe, et al.
Publicado: (2022)

Perspectives for immune plasma treatment of COVID-19
por: SAYINALP, Başak, et al.
Publicado: (2021)

Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature
por: UZ, Burak, et al.
Publicado: (2013)

The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study
por: ÇİFTÇİLER, Rafiye, et al.
Publicado: (2019)

Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
por: Pálmason, Róbert, et al.
Publicado: (2015)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022)

The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients
por: KARATAŞ, Ayşe, et al.
Publicado: (2021)

Prophylactic Central Nervous System Irradiation Is Not Indispensable in Adult Patients with Acute Lymphoblastic Leukemia: A Multicenter Retrospective Cohort Study
por: Çınar, Olgu Erkin, et al.
Publicado: (2022)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis
por: Prem, Shruti, et al.
Publicado: (2019)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_flv7nskdacr6648hnc7j17skjv